1. Home
  2. CTXR vs AIDX Comparison

CTXR vs AIDX Comparison

Compare CTXR & AIDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Citius Pharmaceuticals Inc.

CTXR

Citius Pharmaceuticals Inc.

HOLD

Current Price

$0.67

Market Cap

18.9M

Sector

Health Care

ML Signal

HOLD

AIDX

20/20 Biolabs Inc. Common Stock

N/A

Current Price

$0.86

Market Cap

10.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CTXR
AIDX
Founded
2007
N/A
Country
United States
United States
Employees
N/A
14
Industry
Biotechnology: Pharmaceutical Preparations
Precision Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.9M
10.8M
IPO Year
2010
N/A

Fundamental Metrics

Financial Performance
Metric
CTXR
AIDX
Price
$0.67
$0.86
Analyst Decision
Buy
Analyst Count
2
0
Target Price
$6.00
N/A
AVG Volume (30 Days)
811.4K
218.1K
Earning Date
05-12-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
43.38
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$147.57
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.48
$0.90
52 Week High
$2.38
$14.09

Technical Indicators

Market Signals
Indicator
CTXR
AIDX
Relative Strength Index (RSI) 48.11 15.88
Support Level $0.64 N/A
Resistance Level $0.99 $1.66
Average True Range (ATR) 0.06 0.15
MACD 0.01 -0.01
Stochastic Oscillator 68.05 4.82

Price Performance

Historical Comparison
CTXR
AIDX

About CTXR Citius Pharmaceuticals Inc.

Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.

About AIDX 20/20 Biolabs Inc. Common Stock

20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.

Share on Social Networks: